Falcao, Fatima; Lopes, Carla; Viegas, Erica; Perez, Rita; Aldir, Isabel; Farinha, Helena; Carvalho, Antonio; Mirco, Ana; Marques, Susana; Costa, Tiago Bana E.; Miranda, Ana Claudia; Lebre, Luis; Peixe, Paula; Chagas, Cristina; Mansinho, Kamal; Correia, Jose Manuel published the artcile< Experience of a Portuguese center: effectiveness of direct-acting antiviral therapy for hepatitis C>, SDS of cas: 58-97-9, the main research area is Antiviral Agents/therapeutic use; Hepacivirus/drug effects; Hepatitis C/drug therapy; Portugal.
Introduction: In late 2014, Portugal implemented a national program for the treatment of patients with chronic hepatitis C with directacting antiviral agents. This program has made Portugal one of the first European countries to implement a structured measure of treatment to eliminate this serious public health problem. The aim of this study was to assess the effectiveness of direct-acting antiviral therapy in the treatment of patients with chronic hepatitis C virus infection. Material and Methods: A retrospective observational study was conducted at Centro Hospitalar de Lisboa Ocidental on the national online platform from Dec. 2014 until Feb. 2017 and included patients with hepatitis C virus infection who underwent treatment. The primary endpoint was sustained virol. response at least 12 wk post treatment. Data was analyzed with the SPSS 17.0 program. Results: During the study period, 820 patients completed therapy and achieved sufficient follow-up time to assess sustained virol. response with an overall response rate of 97.2% (n = 797) and a response rate of 98.0%, 99.5%, 90.9%, 95.1% and 94.2% for genotypes 1a, 1b, 2, 3 and 4, resp. Data suggested that advanced fibrosis (F3/F4), human immunodeficiency virus co-infection and treatment failure with interferon and ribavirin were not neg. related with sustained virol. response in our population. Most patients (80.1%) completed treatment with ledipasvir/sofosbuvir ± ribavirin. The most common adverse events were fatigue and insomnia followed by headache and weight loss. Discussion: Patients predominantly had genotype 1 infection which correlates with HCV distribution in Europe, but we found a major proportion in genotype 4 which can be explained by immigration from African countries. Our patients’ ages ranging from 22 to 90 years, reflected a new approach with no upper age limit. Direct-acting antivirals regimens resulted in remarkably high SVR rates compared to interferon-based regimens, which were consistent with clin. trials data. Conclusion: Our data showed that direct-acting antiviral-based regimens are safe and have a high success rate in the treatment of patients with hepatitis C virus infection in a real-world setting.
Acta Medica Portuguesa published new progress about 58-97-9. 58-97-9 belongs to class tetrahydrofurans, and the molecular formula is C9H13N2O9P, SDS of cas: 58-97-9.
Referemce:
Tetrahydrofuran – Wikipedia,
Tetrahydrofuran | (CH2)3CH2O – PubChem